Overview

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma.
Details
Lead Sponsor:
Amgen
Treatments:
Talimogene laherparepvec